Pfizer Inc. (NYSE: PFE) Stock: Q3 Revenue Hits $16.6B as Launched Products Drive 32% Growth

TLDR Pfizer reports $16.6 billion in Q3 revenue as launched products deliver 32% growth. Pfizer raises its 2026 revenue guidance to $62 billion–$64 billion after strong results. Eliquis, Padcev and Lorbrena drive growth as Pfizer expands its medicine portfolio. Paxlovid revenue drops 63%, while Comirnaty sales decline 29% during the quarter. Pfizer maintains adjusted EPS [...]

The post Pfizer Inc. (NYSE: PFE) Stock: Q3 Revenue Hits $16.6B as Launched Products Drive 32% Growth appeared first on Blockonomi.